BST2 impairs Schwann cell function to accelerate age-related hearing loss and serves as a novel serum biomarker
Brief intro:
- Author: Mengxiao Liu, Huan Cao, Qi Li, Huan Yin, Jiantao Wang, Tao Liu, Lei Zhao, Jianwang Yang, Miaomiao An, Yanan Li, Chen Wang & Baoshan Wang
- Journal: Acta Oto-Laryngologica
- Doi: https://www.doi.org/10.1080/00016489.2025.2591707
- Publication Date: 2025/11/30
Abstract
Background
Age-related hearing loss (ARHL) represents the most prevalent sensory disorder among the elderly, significantly impairing daily functioning and increasing the risk of psychiatric conditions. Although Schwann cells (SCs) are critical for maintaining auditory nerve function, the mechanisms underlying their dysfunction in ARHL remain incompletely elucidated.
Aims
To investigate BST2’s role in SCs dysfunction in ARHL and assess its potential value as a serum biomarker for early ARHL diagnosis.
Materials and methods
Adeno-associated virus (AAV) carrying a SC specific promoter—MBP, was injected into the posterior semicircular canal of mice. Immunofluorescence was employed to assess cochlear SCs function, while ELISA was used to measured BST2 levels in the serum of both humans and mice.
Results
Overexpression of BST2 inhibited SCs proliferation and differentiation, promoted apoptosis, and accelerated ARHL. Serum BST2 levels were elevated in both ARHL patients and mice, showing a significant positive correlation with audiometric thresholds and wave I latency of ABR.
Conclusions and significance
BST2 accelerates the progression of ARHL by exacerbating SCs dysfunction and serves as a potential serum biomarker for ARHL.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
